Yohann Loriot

Yohann Loriot

Auto-generated profile, based on publicly available information

Yohann Loriot

Institut Gustave Roussy, University of Paris Sud, Villejuif, France

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2013 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
YLY. Loriot
Y. Loriot
DBD. Bianchini
D. Bianchini
EIE. Ileana
E. Ileana
Shahneen K. SandhuShahneen K. Sandhu
Shahneen K. Sandhu
APA. Patrikidou
A. Patrikidou
CMC. Massard
C. Massard
Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III trials, showing a survival advantage for abiraterone acetate and enzalutamide (MDV3100). The antitumour activity of abiraterone and prednisolone in patients pre-treated with enzalutamide is as yet unknown. We investigated the antitumour activity of abiraterone and prednisolone in patients with mCRPC who had progressed following treatment with docetaxel (Taxotere) and enzalutamide. Clinical data were retrospectively analysed for prostate-specific antigen (PSA) and RECIST responses, clinical benefit and survival. Thirty-eight patients were included in the analysis. The median age was 71 years (range 52–84); metastatic sites included bone disease in 37 patients (97%), lymph nodes in 15 patients (39%) and visceral disease in 10 patients (26%). Abiraterone was well tolerated. Three patients (8%) attained a PSA response, defined as ≥50% decline in PSA confirmed after ≥4 weeks, while seven patients (18%) had a ≥30% PSA decline. The median progression-free survival (PFS) was 2.7 months (95% CI 2.3–4.1). Of the 12 patients assessable radiologically, only 1 (8%) attained a confirmed partial response. Abiraterone and prednisolone have modest antitumour activities in patients with mCRPC pretreated with docetaxel and enzalutamide.

23 July 2009 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
YLY. Loriot
Y. Loriot
LAL. Albiges-Sauvin
L. Albiges-Sauvin
DDD. Dionysopoulos
D. Dionysopoulos
ABA. Bouyon-Monteau
A. Bouyon-Monteau
HBH. Boyle
H. Boyle
TRT. de La Motte Rouge
T. de La Motte Rouge
Background: The aim of this study was to analyze demography, motivation behind the choice of the medical oncology specialty, career plans, and the quality of training in medical oncology and to provide guidance to candidates for boosting the number of oncologists. Methods: In 2007, the French Association of Residents in Oncology conducted a nationwide study of all medical oncology residents in France. Results: The strongest factors that had influenced their decision to become a medical oncology specialist were an interest in medical oncology (98%), exposure to this branch of medicine during graduate training as a medical student (83%), interest in research (81%), and the diversity of the activity (75%). The mean score for the quality of training was 6 (0–10). More time for reading during working hours as well as for attending staff meetings and greater availability of teaching oncologists would improve the quality of training. The most popular career choice was working in a public hospital but most residents stated that they had not received adequate information about the different career plans. Conclusions: No data are available regarding how training in medical oncology is perceived. This study provides useful data for future policies to boost the number of oncologists.

20 January 2012 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
YLY. Loriot
Y. Loriot
CMC. Massard
C. Massard
KFK. Fizazi
K. Fizazi
Prostate cancer is the most common male cancer and one of the top causes of male cancer-related death. Most patients with prostate cancer respond to initial androgen deprivation therapy before progressing to castration-resistant prostate cancer (CRPC) and eventually developing bone metastases. Growth of prostate cancer metastases in the bone microenvironment produces numerous factors that disrupt the dynamic equilibrium of osteogenesis and osteolysis existing in healthy bone, leading to progressive morbidity, poor quality of life, and increased treatment costs. Relevant studies of CRPC and targeted therapies were identified from literature and clinical trial databases, websites, and conference abstracts. Available data on agents potentially targeting bone metastatic CRPC or the bone microenvironment in patients with CRPC are discussed, including inhibitors of tumor growth/survival and bone turnover (SRC family kinase inhibitors, endothelin-1 inhibitors, MET inhibitors, and thalidomide and its derivatives), inhibitors of bone turnover (bisphosphonates and receptor activator of nuclear factor-kB ligand inhibitors), antiangiogenic agents (vascular endothelial growth factor receptor and platelet-derived growth factor blockers), prostate cancer vaccines, and bone-directed radiopharmaceuticals. With increasing data availability demonstrating tumor–bone microenvironment interactions and routine incorporation of bone-related end points into CRPC trials, bone microenvironment-targeted agents are likely to become an increasingly important component of CRPC treatment.

1 May 2014 in European Journal of Cancer
Verified
Journal Article
Closed access
CTConstance Thibault
Constance Thibault
KFKarim Fizazi
Karim Fizazi
DBDaniel Barrios
Daniel Barrios
CMChristophe Massard
Christophe Massard
LALaurence Albiges
Laurence Albiges
YLYohann Loriot
Yohann Loriot

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
MMMichael J. Morris
Michael J. Morris
YLYohann Loriot
Yohann Loriot
CSChristopher Sweeney
Christopher Sweeney
KFKarim Fizazi
Karim Fizazi
CRCharles J. Ryan
Charles J. Ryan
CHCelestia S. Higano
Celestia S. Higano
5075 Background: Radium-223 (Ra-223), an α emitter, and docetaxel (D), a chemotherapy, prolong overall survival (OS) in metastatic castration-resistant prostate cancer (CRPC) patients (pts). This study examined safety and efficacy of Ra-223 + D v D alone. Preliminary phase IIa prostate-specific antigen (PSA) and alkaline phosphatase (ALP) data were previously reported (Morris et al. ASCO 2015). All pts have been randomized and have completed treatment. Methods: D-eligible pts with progressing CRPC and ≥ 2 bone metastases were randomized 2:1 to Ra-223 (50 kBq/kg q 6 wk × 5) + D (60 mg/m2 q 3 wk × 10) v D (75 mg/m2 q 3 wk × 10; step-down option to 60 mg/m2). Primary end point was safety; exploratory efficacy end points were PSA and ALP changes, progression-free survival (PFS), and OS. Results: 53 pts (36 Ra-223 + D; 17 D) were randomized; 33 Ra-223 + D and 13 D pts were treated. For pts in the Ra-223 + D arm, 25 (76%) had all 6 Ra-223 injections, and 20 (61%) had all 10 D cycles. For the D-alone pts, 5 (38%) received all 10 cycles (3 received 75 mg/m2, and 2 stepped down to 60 mg/m2). Pts in Ra-223 + D arm had a lower percentage of grade 3/4 treatment-emergent adverse events during treatment (Ra-223 + D, 49%; D, 62%); no Ra-223 + D and 2 (15%) D pts had febrile neutropenia; no pts had clinically significant thrombocytopenia in either arm. Ra-223 + D had longer time to all measures of progression and longer PFS (Table). Waterfall plots of PSA and ALP will be presented. Two Ra-223 + D pts and one D pt died of disease progression during 9-mo follow-up. Conclusions: Ra-223 + D was well tolerated. Ra-223 + D treated pts had longer times to progression and fewer adverse events v pts in D arm. Further studies of Ra-223 + D are planned. Clinical trial information: NCT01106352.

20 February 2013 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CPCarmel Jo Pezaro
Carmel Jo Pezaro
SMSylvestre Le Moulec
Sylvestre Le Moulec
LALaurence ALBIGES
Laurence ALBIGES
AOAurelius Gabriel Omlin
Aurelius Gabriel Omlin
YLYohann Loriot
Yohann Loriot
CMChristophe Massard
Christophe Massard
155 Background: Cabazitaxel, which is a tubulin-binding chemotherapy, and the CYP-17 androgen biosynthesis inhibitor abiraterone acetate (AA) are both approved for patients with metastatic castration resistant prostate cancer (CRPC) following docetaxel chemotherapy. Recent preclinical data suggest that taxanes impact AR signalling and could imply cross-resistance between new AR targeting treatments and taxane chemotherapy. The aim of this study is to evaluate the antitumor activity of cabazitaxel after AA. Methods: We retrospectively evaluated antitumor activity of cabazitaxel in patients (pts) with metastatic CRPC and progressive disease after docetaxel and AA. Radiological response by RECIST, PSA response by PCWG2 criteria and symptomatic benefit were examined. Results: 89 pts were treated with third-line cabazitaxel, after docetaxel (median 8 cycles; range: 4-12), and AA (median duration of treatment 4.8 months, range: 1-55 months). At cabazitaxel initiation median age was 68 years (range: 53-83), ECOG performance status was 0 or 1 in 70% of pts, and median PSA was 309 ng/ml (range: 3.75-9150). Bone, lymph node and visceral metastases were present in 80 pts (89%), 37 pts (41%), and 12 pts (13%) respectively. An average of 6 cycles of cabazitaxel (range 1-15) were administered. All pts had PSA data available and 44 (49%; 95% CI 39-60%) had a 50% or greater PSA decline. In the 35 pts with RECIST evaluable disease, 7 (20%; 95% CI 8-37%) had a partial response. Conclusions: In men with metastatic CRPC cabazitaxel appears to retain activity in the third-line setting following docetaxel and AA.